Sign in

CIK 0001668243

  • Non-accelerated filer
  • Smaller reporting company

UroGen Pharma Ltd.

Sign in to watch
Ticker
URGN
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
Israel
Entity type
Operating
Phone
+972 97707601
Business address
9 HA'TA'ASIYA ST, RA'ANANA, Israel, 4365007
  1. 4 Open-market sale Chief Medical Officer sold 89 shares at $19.63 ($1,747)
  2. 4 Exercise or conversion Director acquired 3,241 shares (option exercise)
  3. 4 Exercise or conversion Director acquired 1,030 shares (option exercise)
  4. 4 Derivatives Options or other derivatives
  5. 4 Derivatives Options or other derivatives
  6. 4 Derivatives Options or other derivatives
  7. 4 Open-market sale Chief Medical Officer sold 1,076 shares at $22.07 ($23,747)
  8. 4 Open-market sale Chief Medical Officer sold 100 shares at $22.12 ($2,212)
  9. 4 Open-market buy Chief Executive Officer bought 10,000 shares at $18.50 ($185,000)
  10. 4 Open-market sale Chief Medical Officer sold 662 shares at $19.85 ($13,141)
  11. 4 Exercise or conversion Chief Executive Officer acquired 61,652 shares (option exercise)
  12. 4 Open-market sale Chief Medical Officer sold 101 shares at $20.95 ($2,116)
  13. 4 Open-market sale Chief Financial Officer sold 2,400 shares at an average $21.77 ($52,248)
  14. 4 Derivatives Options or other derivatives
  15. 3 Insider Initial Statement of Ownership
  16. 4/A Derivatives Options or other derivatives
  17. 4 Derivatives Options or other derivatives
  18. 3 Insider Initial Statement of Ownership
  19. 4 Open-market sale Chief Medical Officer sold 348 shares at $20.20 ($7,030)
  20. 4 Open-market sale Chief Financial Officer sold 509 shares at $22.82 ($11,615)

Page 8 of 12 · 233 filings